Possibilities of using xylitol and L-arginine drugs in menopause management

Abstract

Menopause is accompanied by the development of a complex of disorders leading to the onset of metabolic syndrome X. In the pathogenesis of these disorders, hypoestrogenemia and hyperandrogenaemia play a significant role, which cause obesity, dyslipidemia, and type 2 diabetes mellitus. Adipose tissue is a «field» for the synthesis of mediators of chronic inflammation and oxidative stress. Unfortunately, hormone replacement therapy is not recognized as an intervention for preventing metabolic disorders. Since metabolic disorders reduce the duration of the period of working capacity and life in general, it is necessary to develop a management program focused on preventing or reducing their negative impact on the woman’s well-being. Xylitol is known as an energy-balancing agent with excellent anticatabolic effects. Recently, it was found that xylitol levels can be used to predict the prospects for weight loss without surgery in morbid obesity patients. The normalization of endothelial function is one of the key tasks in the management of menopausal women. It has been proven that a decrease in the level of nitric oxide in women of transitional age causes the development of vasculopathy. Since L-arginine is a substrate for the synthesis of nitric oxide, the use of its preparations is a promising option for women receiving hormone replacement therapy. The development of a therapeutic and prophylactic strategy using hormone replacement therapy, well-balanced physical activity, diet therapy and the use of xylitol and L-arginine preparations can become a reserve for improving the quality of life of women aged over 45. Possible criteria for assessment the effectiveness of a treatment program designed for six months are blood pressure, body mass index, blood glucose, HOMA index, lipid profile, micronutritients levels, as well as an assessment on the Kuperman scale.